RFK Jr.
5 articles on RFK Jr., written by Shotlee and medically reviewed for clinical accuracy.
RFK Jr. and the Perils of Unapproved Peptides
The mantra 'once an accident, twice a coincidence, three times a trend' fuels bad journalism—and worse, risky medicine. A New Yorker investigation exposes clinics pushing unproven peptides for healing and longevity, backed by RFK Jr. While semaglutide proves the exception, most lack evidence and pose real harms.
5 min read
RFK Jr. Misrepresents Ex-FDA Officials in Push to Lift Peptide Ban
Health Secretary RFK Jr. is pushing to lift the FDA's ban on 19 peptides used in compounding pharmacies, claiming the decision was illegal with no safety signals. But former FDA officials, including Janet Woodcock, say he misrepresents their views amid documented risks like immune reactions and trial fatalities. As demand surges via influencers, recent illnesses highlight the stakes in this regulatory battle.
6 min read
RFK Jr. Big Fan of Peptides: FDA Ban May Lift Soon
Health Secretary RFK Jr. revealed on Joe Rogan's podcast that the FDA may soon act on injectable peptides, which he supports making more accessible. Banned in 2023 for safety risks, these short amino acid chains show promise in anti-aging, muscle building, and more. Here's what peptides are and the debate surrounding them.
5 min read
Hims & Hers Surges After RFK Jr. Pushes Peptide Access on Joe Rogan
Hims & Hers shares surged Monday after HHS Secretary Robert F. Kennedy Jr. expressed urgency on the Joe Rogan Experience to make 14 peptides more accessible. He highlighted FDA's review of the science behind these GLP-1 active ingredients for diabetes and weight loss. This could signal easing regulatory headwinds for telehealth providers like Hims.
5 min read
RFK Jr. Plans to Unban 14 FDA-Banned Peptides, Tells Joe Rogan
RFK Jr. revealed on the Joe Rogan Experience his intent to lift FDA restrictions on 14 banned peptides from compounding pharmacies. This reversal addresses the late 2023 Category 2 list ban amid safety concerns and black market shifts. Patients and wellness advocates await formal decisions in coming weeks.
5 min read